(Total Views: 437)
Posted On: 10/01/2021 2:19:03 PM
Post# of 153905
I see today's price retreat as driven by the molnupiravir results. If they stand, they appear to cut the number of patients needing leronlimab for Covid roughly in half.
How much do we know about its safety? The PRed results were on under 400 people who received the drug very, very recently. All I saw was that AEs were "comparable" to placebo. So our safety guesses are based on MOA, not data, right? Medical people?
Merck wants to give it to 10m people very quickly. Out of every 14 patients treated, 12 would not have gone to a hospital if untreated, 1 will be saved from going, and 1 will go anyway.
Risks, anyone?
How much do we know about its safety? The PRed results were on under 400 people who received the drug very, very recently. All I saw was that AEs were "comparable" to placebo. So our safety guesses are based on MOA, not data, right? Medical people?
Merck wants to give it to 10m people very quickly. Out of every 14 patients treated, 12 would not have gone to a hospital if untreated, 1 will be saved from going, and 1 will go anyway.
Risks, anyone?
(2)
(0)
